Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus AMINOSYN II 15 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus AMINOSYN II 15 IN PLASTIC CONTAINER.
AMINOSYN 7% (PH6) vs AMINOSYN II 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and metabolic processes, providing essential and non-essential amino acids for tissue repair and maintenance.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
AminoSyn 7% (pH 6) is administered intravenously as a component of parenteral nutrition. The typical adult dose is 1.0-1.5 g amino acids/kg/day, infused at a rate not exceeding 0.1 g amino acids/kg/hour. The infusion rate and volume are determined by the patient's metabolic needs, clinical status, and concurrent dextrose and lipid administration.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
None Documented
None Documented
The elimination half-life of individual amino acids varies, typically 0.5-2 hours for most, reflecting rapid incorporation into metabolic pools. For total amino acid mixture, functional half-life is approximately 1-2 hours in patients with normal hepatic and renal function.
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Amino acids in Aminosyn 7% (pH6) are primarily metabolized; excess nitrogen is excreted renally as urea. Approximately 80-90% of infused amino acids are utilized for protein synthesis or metabolized; remaining nitrogen is eliminated as urea via kidneys. Biliary and fecal elimination are negligible.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution